Cytochrome P450 enzymes and drug metabolism in humans

M Zhao, J Ma, M Li, Y Zhang, B Jiang, X Zhao… - International journal of …, 2021 - mdpi.com
Human cytochrome P450 (CYP) enzymes, as membrane-bound hemoproteins, play
important roles in the detoxification of drugs, cellular metabolism, and homeostasis. In …

Drug metabolism in the liver

OA Almazroo, MK Miah… - Clinics in liver …, 2017 - liver.theclinics.com
Drugs are typically small molecules that are generally classified as xenobiotics, which are
foreign to the human body. Several endogenous molecules, however, such as steroids and …

[HTML][HTML] hERG K+ channels: structure, function, and clinical significance

JI Vandenberg, MD Perry, MJ Perrin… - Physiological …, 2012 - journals.physiology.org
The human ether-a-go-go related gene (hERG) encodes the pore-forming subunit of the
rapid component of the delayed rectifier K+ channel, Kv11. 1, which are expressed in the …

Therapeutic potential of resveratrol: the in vivo evidence

JA Baur, DA Sinclair - Nature reviews Drug discovery, 2006 - nature.com
Resveratrol, a constituent of red wine, has long been suspected to have cardioprotective
effects. Interest in this compound has been renewed in recent years, first from its …

Functional coupling of human microphysiology systems: intestine, liver, kidney proximal tubule, blood-brain barrier and skeletal muscle

L Vernetti, A Gough, N Baetz, S Blutt, JR Broughman… - Scientific reports, 2017 - nature.com
Organ interactions resulting from drug, metabolite or xenobiotic transport between organs
are key components of human metabolism that impact therapeutic action and toxic side …

Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4

SF Zhou - Current drug metabolism, 2008 - ingentaconnect.com
Human cytochrome P450 (CYP) 3A4 is the most abundant hepatic and intestinal phase I
enzyme that metabolizes approximately 50% marketed drugs. The crystal structure of bound …

Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer

X Li, C Yang, H Wan, G Zhang, J Feng, L Zhang… - European Journal of …, 2017 - Elsevier
The discovery and development of a novel irreversible EGFR/HER2 dual tyrosine kinase
inhibitor SHR1258 (pyrotinib) for the treatment of HER2-postive breast cancer is presented …

Statin safety: a systematic review

M Law, AR Rudnicka - The American journal of cardiology, 2006 - Elsevier
A systematic review of cohort studies, randomized trials, voluntary notifications to national
regulatory authorities, and published case reports was undertaken to assess the incidence …

Sex differences in drug disposition

OP Soldin, SH Chung… - BioMed Research …, 2011 - Wiley Online Library
Physiological, hormonal, and genetic differences between males and females affect the
prevalence, incidence, and severity of diseases and responses to therapy. Understanding …

Review – Treatment of Helicobacter pylori infection 2020

A O'Connor, T Furuta, JP Gisbert, C O'Morain - Helicobacter, 2020 - Wiley Online Library
This review summarizes important studies regarding Helicobacter pylori therapy published
from April 2019 to April 2020. The main themes that emerge involve studies assessing …